Document:

Document

Exhibit 10.20

RESTRICTIVE COVENANT AND CONFIDENTIALITY AGREEMENT
In exchange for the mutual promises and consideration set forth below, this Restrictive Covenant and Confidentiality Agreement (“Agreement”) is entered into by and between the Federal Home Loan Mortgage Corporation (“Freddie Mac” or “Company”) and the undersigned employee (“you”), effective on the date you assign a personal signature at the conclusion of this Agreement.  This Agreement supersedes any previous Restrictive Covenant and Confidentiality Agreement between the above parties.
I.    Definitions
The following terms shall have the meanings indicated when used in this Agreement.
A.  Competitor:  The following entities, and their respective parents, successors, subsidiaries, and affiliates are competitors: (i) Fannie Mae (ii) all Federal Home Loan Banks (including the Office of Finance); and (iii) such other entities to which you and the Company may agree in writing from time-to-time.
B.   Confidential Information:  Information or materials in written, oral, magnetic, digital, computer, photographic, optical, electronic, or other form, whether now existing or developed or created during the period of your employment with Freddie Mac, that constitutes trade secrets and/or proprietary or confidential information.  This information includes, but is not limited to:  (i) all information marked Proprietary or Confidential; (ii) information concerning the components, capabilities, and attributes of Freddie Mac’s business plans, methods, and strategies; (iii) information relating to tactics, plans, or strategies concerning shareholders, investors, pricing, investment, marketing, sales, trading, funding, hedging, modeling, sales and risk management; (iv) financial or tax information and analyses, including but not limited to, information concerning Freddie Mac’s capital structure and tax or financial planning; (v) confidential information about Freddie Mac’s customers, borrowers, employees, or others; (vi) pricing and quoting information, policies, procedures, and practices; (vii) confidential customer lists; (viii) proprietary algorithms; (ix) confidential contract terms; (x) confidential information concerning Freddie Mac’s policies, procedures, and practices or the way in which Freddie Mac does business; (xi) proprietary or confidential data bases, including their structure and content; (xii) proprietary Freddie Mac business software, including its design, specifications and documentation; (xiii) information about Freddie Mac products, programs, and services which has not yet been made public; (xiv) confidential information about Freddie Mac’s dealings with third parties, including dealers, customers, vendors, and regulators; and/or (xv) confidential information belonging to third parties to which you received access in connection with your employment with Freddie Mac.  Confidential Information does not include general skills, experience, or knowledge acquired in connection with your employment with Freddie Mac that otherwise are generally known to the public or within the industry or trade in which Freddie Mac operates.
II.    Compliance with the Code of Conduct and Corporate Policies & Procedures, Including the Personal Investments Policy, Following Commencement of Employment With Freddie Mac
As a Freddie Mac employee, you will be subject to Freddie Mac’s Code of Conduct (“Code”) and to Corporate Policy 3-206, Personal Investments Policy (“Policy”) that, among other things, limit the investment activities of Freddie Mac employees. You agree to fully comply with the Code and the Policy, copies of which are enclosed for your review. 
You agree to consult with Freddie Mac’s Chief Compliance Officer as soon as practical prior to beginning employment with Freddie Mac about any investments that you or a “covered household member,” as that term is defined in the Policy, may have that may be prohibited by the Policy.  You also agree to disclose prior to beginning employment with Freddie Mac any other matter or situation that may create a conflict of interest as such term is defined in the Code.  
In addition, prior to beginning employment with Freddie Mac, you agree to disclose to Freddie Mac's Human Resources Division the terms of any employment, confidentiality or stock grant agreements to which you may currently be subject that may affect your future employment or recruiting activities so that Freddie Mac may ensure that your employment by Freddie Mac and conduct as a Freddie Mac employee are not inconsistent with any of their terms. 
III.    Non-Competition
You recognize that as a result of your employment with Freddie Mac, you have access to and knowledge of Confidential Information, the improper disclosure or use of which would result in grave competitive harm to Freddie Mac.  Therefore, you agree that neither during your employment with Freddie Mac, nor for the twelve (12) months immediately following termination of your employment for any reason, will you consider offers of employment from, seek or accept employment with, or otherwise 

directly or indirectly provide professional services to any Competitor, if you will be rendering duties, responsibilities or services for the Competitor that are of the type and nature rendered or performed by you during the past two years of your employment with Freddie Mac.  You acknowledge and agree that this covenant has unique, substantial and immeasurable value to Freddie Mac, that you have sufficient skills to provide a livelihood for yourself while this covenant remains in force, and that this covenant will not interfere with your ability to work consistent with your experience, training and education.  This non-competition covenant applies regardless of whether your employment is terminated by you, by Freddie Mac, or by a joint decision. 
If you are a licensed lawyer, this non-competition covenant shall be interpreted in a manner consistent with any rule applicable to a licensed legal professional in the jurisdiction(s) of your licensure or registration that concerns your employment as counsel with, or provision of legal services to, a Competitor.
IV.    Non-Solicitation and Non-Recruitment
During Your employment with Freddie Mac and for a period of twelve (12) months after your termination date, you will not solicit or recruit, attempt to solicit or recruit or assist another in soliciting or recruiting any Freddie Mac managerial employee (including manager-level, Executive-level, or officer-level employee) with whom you worked, or any employee whom you directly or indirectly supervised at Freddie Mac, to leave the employee’s employment with Freddie Mac for purposes of employment or for the rendering of professional services.  This prohibition against solicitation does not apply if Freddie Mac has notified the employee being solicited or recruited that his/her employment with the Company will be terminated pursuant to a corporate reorganization, reduction-in-force, involuntary termination or voluntary early retirement program.
If you are a licensed lawyer, this non-solicitation covenant shall be interpreted in a manner consistent with any rule applicable to a licensed legal professional in the jurisdiction(s) of your licensure or registration.
V.    Treatment of Confidential Information During and Following Employment With Freddie Mac
A.Non-Disclosure.  You recognize that Freddie Mac is engaged in an extremely competitive business and that, in the course of performing your job duties, you will have access to and gain knowledge about Confidential Information.  You further recognize the importance of carefully protecting this Confidential Information in order for Freddie Mac to compete successfully.  Therefore, you agree that both during and following your employment with Freddie Mac, you will neither divulge Confidential Information to any persons, including to other Freddie Mac employees who do not have a Freddie Mac business-related need to know, nor make use of the Confidential Information for your own benefit or for the benefit of anyone else other than Freddie Mac.  You further agree to take all reasonable precautions to prevent the disclosure of Confidential Information to unauthorized persons or entities, and to comply with all Company policies, procedures, and instructions regarding the treatment of such information.
B.Disclosure of Trade Secrets to Government.  As required by federal law, and notwithstanding anything to the contrary in this Agreement:
i.You shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that is made in confidence to a Federal, State, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law.
ii.You shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if the filing is made under seal. 
iii.If you file a lawsuit for retaliation by Freddie Mac for reporting a suspected violation of law, you may (a) disclose trade secrets to your attorney, and (b) use the trade secret information in the court proceeding if you file any document containing the trade secret under seal and do not disclose the trade secret except pursuant to court order.
C.   Ability to Enforce Agreement and Assist Government Investigations.  Nothing in this Agreement prohibits or otherwise restricts you from:  (1) making any disclosure of information required by law; (2) assisting any regulatory or law enforcement agency or legislative body to the extent you maintain a legal right to do so notwithstanding this Agreement; (3) filing, testifying, participating in or otherwise assisting in a proceeding relating to the alleged violation of any federal, state, or local law, regulation, or rule, to the extent you maintain a legal right to do so notwithstanding this Agreement; or (4) filing, testifying, participating in or otherwise assisting the Securities and Exchange Commission or any other proper authority in a proceeding relating to allegations of fraud.
VI.    Additional Post-Employment Obligations
A.  Return of Materials.  You agree that upon termination of your employment with Freddie Mac for any reason whatsoever, you will deliver to your immediate supervisor all tangible materials embodying Confidential Information, including, but not limited to, any documentation, records, listings, notes, files, data, sketches, memoranda, models, accounts, reference materials, samples, machine-readable media, computer disks, tapes, and equipment which in any way relate to Confidential Information, whether developed by you or not.  You further agree not to retain any copies of any materials embodying Confidential Information.

B.   Disclosure of Future Employment.  To enable Freddie Mac to monitor compliance with the obligations imposed by this Agreement, you further agree to notify Freddie Mac by email to Term_notification@freddiemac.com the identity of your subsequent employer(s) and your prospective job title and responsibilities prior to beginning employment, if you did not disclose this information to the Human Resources Division at the conclusion of your employment with Freddie Mac.  You agree that this notice requirement shall remain in effect for twelve (12) months following the termination of your Freddie Mac employment.
C.  Contact With Future Employers.  You agree that, in order to assure the continued confidentiality of the Confidential Information, Freddie Mac may correspond with your future employers to advise them generally of your exposure to and knowledge of Confidential Information, and your obligations and responsibilities regarding the Confidential Information.  You understand and agree that any such contact may include a request for assurance and confirmation from such employer(s) that you will not disclose Confidential Information to such employer(s), nor will such employer(s) permit any use whatsoever of the Confidential Information.
D.  Participation in Business Transactions Involving Freddie Mac.  In order to protect Freddie Mac’s Confidential Information as defined herein, after your separation of employment from Freddie Mac, you are prohibited from participating directly or indirectly in any Business Transaction involving Freddie Mac, on behalf of yourself or a third party, for a period of ninety (90) calendar days following your date of termination of employment.  For purposes of this paragraph, “Business Transaction” shall mean business engagements between Freddie Mac and third parties involving the purchase or sale of securities, properties or mortgages.  Questions regarding the scope of this prohibition should be directed to the Compliance Helpline. 
VII.    Consideration Given to You
In exchange for agreeing to be bound by the terms, conditions, and restrictions stated in this Agreement, Freddie Mac will provide you with:
A.Employment (offer of employment or continued employment), and
B.Participation in either Freddie Mac’s Incentive Program for Vice Presidents and Non-Officers (if you are a Vice President), or Freddie Mac’s Executive Management Compensation Program (if you are a Senior Vice President or above).
which you agree is adequate consideration for your agreement to be bound by the provisions of this Agreement.
VIII.         Reservation of Rights
You agree that nothing in this Agreement constitutes a contract or commitment by Freddie Mac to continue your employment in any job position for any period of time, nor does anything in this Agreement limit in any way Freddie Mac’s right to terminate your employment at any time for any reason.
IX.    Absence of Any Conflict of Interest
You represent that you do not have any confidential information, trade secrets or other proprietary information that you obtained as the result of your employment with another employer that you will be using in your position at Freddie Mac.  You also represent that you are not subject to any employment, confidentiality or stock grant agreements, or any other restrictions or limitations imposed by a prior employer, which would affect your ability to perform the duties and responsibilities for Freddie Mac in the job position offered, and further represent that you have provided Freddie Mac with copies of any non-competition, non-solicitation or similar agreements or limitations that have not expired, so that Freddie Mac can make an independent judgment that your employment with Freddie Mac is not inconsistent with any of its terms.
X.    Enforcement
A.You acknowledge that during your employment with Freddie Mac, you may be subject to corrective action, up to and including termination of employment, for your breach or threat of breach of any provision of this Agreement.  You further agree that, following the conclusion of your employment with Freddie Mac, Freddie Mac may contact your future employers or take other legal steps necessary to protect Freddie Mac Confidential Information from improper use or disclosure.
B.You acknowledge that in the event that you breach any provision of this Agreement during or after your employment with Freddie Mac, you may be subject to a recapture or forfeiture of i) any incentive pay under the Incentive Program for Vice Presidents and Non-Officers or ii) any Deferred Salary pay under the Executive Management Compensation Program, notwithstanding the terms of any program, plan, agreement or award to the contrary.  Such recapture or forfeiture shall be limited to such pay earned within three years prior to or two years after the date of the breach, or any severance pay paid or payable to you by Freddie Mac, This recapture and forfeiture provision shall not apply to incentive, Deferred Salary or severance pay paid or earned prior to 2021.  The Board of Directors, in the case of senior officers, and the CEO, in the case of vice presidents, in the good faith exercise of their sole discretion shall determine the appropriate dollar amount and type of compensation to be recaptured from and/or forfeited by you, if any.  The Board of Directors, in the case of senior officers, and the CEO, in the case of vice presidents, will consider certain factors when determining the dollar amount for recapture and forfeiture including: materiality of the violation and proportionality of the violation as compared to the amount of compensation subject to recapture and forfeiture.

C.You agree that irreparable injury will result to Freddie Mac’s business interests in the event of breach or threatened breach of this Agreement, the full extent of Freddie Mac’s damages will be impossible to ascertain, and monetary damages will not be an adequate remedy for Freddie Mac.  Therefore, you agree that in the event of a breach or threat of breach of any provision(s) of this Agreement, Freddie Mac, in addition to any other relief available, shall be entitled to temporary, preliminary, and permanent equitable relief to restrain any such breach or threat of breach by you and all persons acting for and/or in concert with you, without the necessity of posting bond or security, which you expressly waive.
D.You agree that each of your obligations specified in this Agreement is a separate and independent covenant, and that all of your obligations set forth herein shall survive any termination, for any reason, of your Freddie Mac employment.  To the extent that any provision of this Agreement is determined by a court of competent jurisdiction to be unenforceable because it is overbroad, that provision shall be limited and enforced to the extent permitted by applicable law.  Should any provision of this Agreement be declared or determined by any court of competent jurisdiction to be unenforceable or invalid under applicable law, the validity of the remaining obligations will not be affected thereby and only the unenforceable or invalid obligation will be deemed not to be a part of this Agreement.
E.This Agreement is governed by, and will be construed in accordance with, the laws of the Commonwealth of Virginia, without regard to its or any other jurisdiction’s conflict-of-law provisions.  You agree that any action related to or arising out of this Agreement shall be brought exclusively in the United States District Court for the Eastern District of Virginia, and you hereby irrevocably consent to personal jurisdiction and venue in such court and to service of process by United States Mail or express courier service in any such action.
F.If any dispute(s) arise(s) between Freddie Mac and you with respect to any matter which is the subject of this Agreement, the prevailing party in such dispute(s) shall be entitled to recover from the other party all of its costs and expenses, including its reasonable attorneys’ fees.
XI.    At-Will Employment Relationship
Nothing in this Agreement is intended or shall be construed to abrogate the “at will” employment relationship between you and Freddie Mac, and both you and Freddie Mac retain the right to terminate the employment relationship at any time for any lawful reason with or without notice.Exhibit
10.7

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO NEXIEN BIOPHARMA,
INC.

 

CONVERTIBLE
PROMISSORY NOTE

 

	$40,000.00	Denver,
                                         Colorado

        November
        24 , 2020

 

FOR
VALUE RECEIVED, the undersigned, Nexien BioPharma, Inc., a Delaware corporation (the “Maker”), promises
to pay to the order of Richard Greenberg, an individual residing in Colorado (“Payee”), on or before
three (3) years from the date hereof (the “Maturity Date”), the amount of Forty Thousand Dollars ($40,000.00),
together with interest accruing in arrears on the unpaid principal balance from the date Payee has disbursed such funds to Maker,
at the rate of eight percent (8%) per annum. Interest shall be computed hereunder on the basis of a 365-day year for the actual
number of days elapsed and compounded annually. All amounts payable hereunder are payable in lawful money of the United States
of America in immediately available funds. All payments shall be applied first to interest and then to the principal indebtedness
owed to Payee.

 

Conversion.
At any time, Payee shall have the option to convert all or any part of the unpaid principal balance and accrued interest of this
promissory note (the “Note”) into unregistered shares of Maker’s common stock (the “Shares”)
on the terms and conditions set forth below (the “Conversion Option”).

 

(a) Upon
conversion, the number of Shares that shall be issued by Maker shall equal the number derived by dividing: (i) the sum of the
Note principal and accrued interest to be converted by $0.037631 (the “Conversion Price”), being the
volume-weighted average price of Maker’s common stock over the ten (10) trading days immediately preceding the date of this
Note.

 

(b) To
exercise the Conversion Option, Payee shall surrender this Note to the Maker, accompanied by written notice of Payee’s intention
to exercise the Conversion Option (the “Notice of Conversion”). Within ten (10) business days of Maker’s
receipt of the Notice of Conversion and Payee’s surrender of this Note, the Maker shall deliver an electronic or physical
certificate representing the Shares to Payee, registered in the name of Payee or Payee’s designee. Interest shall cease
to accrue under this Note upon Maker’s receipt of such Notice of Conversion. When delivered, the Shares shall be duly authorized,
validly issued, fully paid, and nonassessable. Maker shall take all action necessary to maintain the required authority to issue
the Shares to Payee in the event Payee exercises the Conversion Option.

 

    	1

     

    

 

Adjustment
to Conversion Price. If Maker, at any time while the Note is outstanding, shall, other than in an Exempt Issuance transaction,
issue shares of its Common Stock or rights, options or warrants with respect to its Common Stock at a price per share that is
lower than the Conversion Price, then the Conversion Price shall be reduced to an amount equal to such consideration per share.
Such adjustment shall be made whenever such shares, rights or warrants are issued, and shall become effective immediately after
the issuance of the shares or the record date for the determination of stockholders entitled to receive such rights, options or
warrants, as the case may be.

 

Exempt
Issuance. An “Exempt Issuance” shall mean issuance of (a) shares of Common Stock or options to employees, officers
or directors of Maker pursuant to any stock or option plan duly adopted for such purpose by a majority of the members of the Board
of Directors of Maker or a majority of the members of a committee of directors established for such purpose by the Board of Directors
of Maker; (b) securities upon the exercise or exchange of or conversion of any securities issued under Maker’s offering
of convertible promissory notes and warrants of which this Note is a part and/or other securities exercisable or exchangeable
for or convertible into shares of Common Stock issued and outstanding on the date of this Note, provided that such securities
have not been amended since the date of this Note to increase the number of such securities or to decrease the exercise, exchange
or conversion price of such securities; and (c) securities issued pursuant to acquisitions or strategic transactions approved
by a majority of the disinterested directors of Maker, provided that any such issuance shall not include a transaction in which
Maker is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in
securities.

 

Default.
If Maker shall fail to perform any of the terms, agreements, covenants, or conditions contained in this Note for a period of ten
(10) days after the giving of written notice from Payee to Maker, the entire unpaid balance of this Note, including principal
and accrued interest, shall, at the election of Payee, and without further notice of such election, become immediately due and
payable; and the entire principal balance and accrued interest, in the event of acceleration, shall bear interest thereafter at
the rate of eighteen percent (18%) per annum until paid in full. In addition, Payee shall have the right to specifically enforce
its right to exercise the Option to convert this Note to Shares as set forth above. Notwithstanding anything hereinabove to the
contrary, if the interest payable as provided hereinabove at any time shall exceed the maximum lawful rate of interest under the
laws of the State of Colorado, the excess shall be applied to and considered as payment of principal.

 

Attorneys’
Fees. Maker agrees to reimburse Payee for all reasonable costs and expenses, including attorneys’ fees and court costs,
incurred to enforce this Note.

 

Waiver.
Maker, and all others now or hereafter obligated hereon, whether primarily or secondarily, hereby waive presentment, demand for
payment, protest for nonpayment, notice of dishonor, diligence in collection, and all other indulgences.

 

    	2

     

    

 

Prepayment
Right. Maker shall have the right to pre-pay this Note at any time, without penalty.

 

Colorado
Law. This Note shall be governed by and interpreted in accordance with the laws of the State of Colorado.

 

General
Provisions. This Note may not be amended, modified, or changed, nor shall any waiver of any provision hereof be effective,
except only by an instrument in writing and signed by the party against whom enforcement of any waiver, amendment, change, modification,
or discharge is sought.

 

Severability.
If any provision of this Note shall be deemed invalid or unenforceable by a court of competent jurisdiction, it shall be modified
by said court to the extent necessary to make it valid and enforceable, and shall be valid and enforceable to the extent so modified.

 

Assignment.
This Note, and the rights and obligations hereunder, may be assignable by Payee, subject to compliance with applicable securities
laws, but are not assignable by Maker without the prior written consent of Payee.

 

Successors.
Whenever used herein, the words “Maker” and “Payee” shall be deemed to include their respective successors
and permitted assigns.

 

	 	 	Nexien
    BioPharma, Inc.
	 	 	a
    Delaware corporation:
	 	 	 	 
	 	 	By:	/s/
    Evan Wasoff
	 	 	 	Evan
    Wasoff, Chief Financial Officer

 

    	3

     

    

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

CLASS
A PURCHASE WARRANT

 

NEXIEN
BIOPHARMA, INC.

 

Issue
Date: November 24, 2020

Warrant
No. A-001

 

THIS
CLASS A PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Richard Greenberg
(the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after the Issue Date (the “Initial Exercise Date”) and on or
prior to 5:00 p.m. Mountain Time on November 24, 2025 (the “Termination Date”) but not thereafter,
to subscribe for and purchase from NEXIEN BIOPHARMA, INC., a Delaware corporation (the “Company”), up
to 1,062,953 shares of Common Stock (the “Warrant Shares”) at a price equal to the lesser of
(i) $0.040265 per share and (ii) 107% of the Conversion Price of that certain Convertible Promissory Note made and delivered as
of the Issue Date of this Warrant to the Holder in effect as of the date of exercise (the “Exercise Price”).

 

Section
1. Exercise.

 

a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date, by delivery to the Company (or such
other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the
Holder appearing on the books of the Company) of a facsimile or scanned copy of the duly executed Notice of Exercise Form annexed
hereto; and, within 3 Business Days of the date said Notice of Exercise is delivered to the Company, the Company shall have received
payment of the aggregate Exercise Price of the Warrant Shares thereby purchased by wire transfer or cashier’s check drawn
on a United States bank. The Holder shall not be required to physically surrender this Warrant to the Company upon exercise. Partial
exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall
have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable
number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased
and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within 2 Business Days
of receipt of such notice. In the event of any dispute or discrepancy, the records of the Company shall be controlling and determinative
in the absence of manifest error. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by
reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of
Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

    	 

     

    

 

(b)
Mechanics of Exercise.

 

i.
Delivery of Certificates Upon Exercise. Certificates for Warrant Shares purchased hereunder shall be delivered to the address
specified by the Holder in the Notice of Exercise within the first 10 Business Days of the month following the month in which
the Notice of Exercise Form and payment of the aggregate Exercise Price is delivered to the Company (the “Delivery
Date”). This Warrant shall be deemed to have been exercised on the date the Exercise Price is received by the Company.
The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall
be deemed to have become a holder of record of such Warrant Shares for all purposes, as of the date the Warrant has been exercised
by payment to the Company of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to Section
1(b)(v) prior to the issuance of such securities, have been paid.

 

ii.
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing
Warrant Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called
for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

 

iii.
Rescission Rights. If the Company fails to deliver to the Holder a certificate or the certificates representing the Warrant
Shares pursuant to Section 1(b)(i) by the Delivery Date, then, the Holder will have the right to rescind such exercise.

 

iv.
No Fractional Shares or Scrip. No fractional Shares or scrip representing fractional Warrant Shares shall be issued upon
the exercise of this Warrant. As to any fraction of a Share which Holder would otherwise be entitled to purchase upon such exercise,
the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such
fraction multiplied by the Exercise Price or round up to the next whole Share.

 

v.
Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for
any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses
shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may
be directed by the Holder; provided, however, that in the event certificates for Warrant Shares are to be issued in a name
other than the name of the Holder, the Holder shall deliver to the Company the Assignment Form attached hereto duly executed by
the Holder, and follow the requirements set forth in Section 3(d). The Company may require, as a condition thereto, the
payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.

 

    	Nexien BioPharma, Inc. Class A Purchase Warrant – page 2

     

    

 

vi.
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

(c)
Cashless Exercise. This Warrant may also be exercised, in whole or in part, at such time by means of a “cashless
exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by
dividing [(A-B) (X)] by (A), where:

 

	 	(A)
    = 	the
    VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a “cashless
    exercise,” as set forth in the applicable Notice of Exercise;
	 	 	 
	 	(B)
    = 	the
    Exercise Price of this Warrant, as adjusted hereunder; and
	 	 	 
	 	(X)
    = 	the
    number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
    if such exercise were by means of a cash exercise rather than a cashless exercise.

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised, and the
holding period of the Warrants being exercised may be tacked on to the holding period of the Warrant Shares. The Company agrees
not to take any position contrary to this Section 1(c).

 

Section
2. Certain Adjustments.

 

a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event and the number of Warrant Shares issuable upon exercise of this Warrant shall be proportionately
adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section
2(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such
dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.

 

    	Nexien BioPharma, Inc. Class A Purchase Warrant – page 3

     

    

 

b)
Calculations. All calculations under this Section 2 shall be made to the nearest cent or the nearest 1/100th of
a share, as the case may be. For purposes of this Section 2, the number of shares of Common Stock deemed to be issued and
outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued
and outstanding.

 

c)
Notice to Holder.

 

i.
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 2,
the Company shall promptly mail/e-mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting
forth a brief statement of the facts requiring such adjustment.

 

ii.
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a
party, any sale or transfer of all or substantially all of the assets of the Company, of any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed/emailed
to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 5 Business Days prior
to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken
for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is
expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall
be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or
in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice.

 

The
Holder is entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the
event triggering such notice.

 

Section
3. Transfer of Warrant.

 

a)
Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section 3(c)
hereof, this Warrant and all rights hereunder are transferable, in whole only, upon surrender of this Warrant at the principal
office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached
hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making
of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant in the
name of the assignee, and this Warrant shall promptly be cancelled. The Warrant, if properly assigned, may be exercised by a new
holder for the purchase of Warrant Shares without having a new Warrant issued.

 

    	Nexien BioPharma, Inc. Class A Purchase Warrant – page 4

     

    

 

b)
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

c)
Transfer Restrictions. Any requested transfer of this Warrant, in whole only, shall be made by delivering to the Company
the Assignment Form and a Certificate of Accredited Investor Status completed by the proposed transferee(s). If the requested
transfer is approved by the Company in its sole discretion, a new Warrant shall be issued to the transferee(s).

 

Section
4. Miscellaneous.

 

a)
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 1(b)(i).

 

b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.

 

d)
Authorized Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized
and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of
any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full
authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates
for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable
law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant, be duly authorized, validly issued, fully paid and nonassessable and free
from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
occurring contemporaneously with such issue).

 

    	Nexien BioPharma, Inc. Class A Purchase Warrant – page 5

     

    

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.

 

e)
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be determined in accordance with the corporate laws of the State of Delaware.

 

f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
will have restrictions upon resale imposed by state and federal securities laws.

 

g)
Nonwaiver. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the fact that all
rights hereunder terminate on the Termination Date.

 

h)
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company
shall be delivered to the Holder at his/her/its last known address appearing in the Warrant Register of the Company.

 

i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability
of Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.

 

    	Nexien BioPharma, Inc. Class A Purchase Warrant – page 6

     

    

 

j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not
be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be
enforceable by the Holder or holder of Warrant Shares.

 

l)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and Holders holding at least a majority of the outstanding Class A Warrants.

 

m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.

 

********************

 

(Signature
Page Follow)

 

    	Nexien BioPharma, Inc. Class A Purchase Warrant – page 7

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Class A Warrant to be executed by its officer thereunto duly authorized as of the
date first above indicated.

 

	 	NEXIEN
    BIOPHARMA, INC.
	 	 
	 	By:
    	/s/
    Evan Wasoff
	 	 	Evan
    Wasoff, Chief Financial Officer

 

    	Nexien BioPharma, Inc. Class A Purchase Warrant – page 8

     

    

 

NOTICE
OF EXERCISE

 

	TO:
    	NEXIDEN
    BIOPHARMA INC.

 

	(1)	The
    undersigned hereby elects to purchase ________ shares of Common Stock of the Company (the “Warrant Shares”)
    pursuant to the terms of the attached Class A Warrant (only if exercised in full), and tenders herewith payment of the exercise
    price in full, together with all applicable transfer taxes, if any.
	 	 
	(2)	Please
    issue a certificate or certificates representing said Warrant Shares [  ] in the name of the undersigned or [  ]
    in such other name as is specified below:

 

	 
	 

 

	(3)	The
    undersigned acknowledges that the Warrant Shares have not been registered under the Securities Act of 1933, as amended (the
    “1933 Act”). Accordingly, the undersigned acknowledges, represents, warrants and agrees as follows:
	 	 	 
	 	a)	The
    Warrant Shares are being acquired for the undersigned’s own account for investment purposes only and with no view to
    their resale or other distribution of any kind, and no other person (except the spouse of the undersigned, if married) will
    own any interest therein.
	 	 	 
	 	b)	The
    undersigned will not sell or dispose of the Warrant Shares in violation of the 1933 Act, or any other applicable federal or
    state securities laws.
	 	 	 
	 	c)	The
    undersigned agrees that the Company may, without liability for its good faith actions, place legend restrictions upon the
    Warrant Shares and issue “stop transfer” instructions requiring compliance with applicable securities laws and
    the terms of the Class A Warrant.
	 	 	 
	 	d)	The
    undersigned represents, warrants and agrees, as of the date of this Notice of Exercise, that the undersigned continues to
    be an “accredited investor” as defined in the rules and regulations promulgated under the 1933 Act.

 

	 	 	 
	Name
    of Holder (Printed)	 	Signature
	 	 	 
	 	 	 
	Name
    of Holder’s Spouse (if name appears on this Warrant)	 	Title
    (if applicable)
	 	 	 
	 	 	 
	Date	 	Address

                                                                                            

         

 

    	Nexien BioPharma, Inc. Class A Purchase Warrant – page 9

     

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing warrant, execute this form and supply required information.

Do
not use this form to exercise the warrant.)

 

FOR
VALUE RECEIVED, [____] all of or [_______] Warrants of the foregoing Warrant and all rights evidenced thereby are hereby assigned
to

 

________________________________________________________________________________
whose address is

 

_______________________________________________________________________________________________

 

_______________________________________________________________________________________________ 

 

	 	 	 
	Name
    of Holder (Printed)	 	Signature
	  
	 	  

	Name
                                         of Holder’s Spouse (if name appears on this Warrant)

         

         
	 	Title
                                         (if applicable)

         

         

	Date	 	Address

         

         

 

    	Nexien BioPharma, Inc. Class A Purchase Warrant – page 10

     

    

 

CERTIFICATE
OF ACCREDITED INVESTOR STATUS

 

Except
as may be indicated by the undersigned below, the undersigned is an individual “accredited investor,” as that term
is defined in Regulation D under the Securities Act of 1933, as amended (the “Act”). The undersigned has checked
the box below indicating the basis on which it is representing its status as an “accredited investor”:

 

	[  ]	a
    bank as defined in Section 3(a)(2) of the Act, or any savings and loan association or other institution as defined in Section
    3(a)(5)(A) of the Act whether acting in its individual or fiduciary capacity; a broker or dealer registered pursuant to Section
    15 of the Securities Exchange Act of 1934; an insurance company as defined in Section 2(a)(13) of the Act; an investment company
    registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that
    act; a small business investment company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of
    the Small Business Investment Act of 1958; a plan established and maintained by a state, its political subdivisions, or any
    agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total
    assets in excess of $5,000,000; an employee benefit plan within the meaning of the Employee Retirement Income Security Act
    of 1974, if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such act, which is either
    a bank, savings and loan association, insurance company, or registered investment adviser, or if the employee benefit plan
    has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons that
    are “accredited investors”;
	 	 
	[  ]	a
    private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940;
	 	 
	[  ]	an
    organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts or similar business trust,
    or partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000;
	 	 
	[  ]	a
    natural person whose individual net worth, or joint net worth with the undersigned’s spouse, excluding the “net
    value” of his or her primary residence, at the time of this purchase exceeds $1,000,000 and having no reason to believe
    that net worth will not remain in excess of $1,000,000 for the foreseeable future, with “net value” for such purposes
    being the fair value of the residence less any mortgage indebtedness or other obligation secured by the residence, but subtracting
    such indebtedness or obligation only if it is a liability already considered in calculating net worth;
	 	 
	[  ]	a
    natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with
    the undersigned’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the
    same income level in the current year;
	 	 
	[  ]	a
    trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered,
    whose purchase is directed by a person who has such knowledge and experience in financial and business matters that he is
    capable of evaluating the merits and risks of the prospective investment; or
	 	 
	[  ]	an
    entity in which all of the equity holders are “accredited investors” by virtue of their meeting one or more of
    the above standards.
	 	 
	[  ]	an
    individual who is a director or executive officer of Intiva BioPharma Inc.

 

IN
WITNESS WHEREOF, the undersigned has executed this Certificate of Accredited Investor Status effective as of __________________,
20__.

 

	Date:
    	 	 	 
	 	 	 	Subscriber
    Name (Printed)
	 	 	 	 	           
	 	 	 	By:	 
	 	 	 	 	 
	 	 	 	Name:	 
	 	 	 	 	 
	 	 	 	Title:	 

 

    	Nexien BioPharma, Inc. Class A Purchase Warrant – page 11

     

    

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

CLASS
B PURCHASE WARRANT

 

NEXIEN
BIOPHARMA, INC.

 

Issue
Date: November 24, 2020

Warrant
No. B-001

 

THIS
CLASS B PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Richard Greenberg
(the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after the Issue Date (the “Initial Exercise Date”) and on or
prior to 5:00 p.m. Mountain Time on November 24, 2025 (the “Termination Date”) but not thereafter,
to subscribe for and purchase from NEXIEN BIOPHARMA, INC., a Delaware corporation (the “Company”), up
to 1,062,953 shares of Common Stock (the “Warrant Shares”) at a price equal to the lesser of
(i) $0.043276 per share and (ii) 115% of the Conversion Price of that certain Convertible Promissory Note made and delivered as
of the Issue Date of this Warrant to the Holder in effect as of the date of exercise (the “Exercise Price”).

 

Section
1. Exercise.

 

a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date, by delivery to the Company (or such
other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the
Holder appearing on the books of the Company) of a facsimile or scanned copy of the duly executed Notice of Exercise Form annexed
hereto; and, within 3 Business Days of the date said Notice of Exercise is delivered to the Company, the Company shall have received
payment of the aggregate Exercise Price of the Warrant Shares thereby purchased by wire transfer or cashier’s check drawn
on a United States bank. The Holder shall not be required to physically surrender this Warrant to the Company upon exercise. Partial
exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall
have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable
number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased
and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within 2 Business Days
of receipt of such notice. In the event of any dispute or discrepancy, the records of the Company shall be controlling and determinative
in the absence of manifest error. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by
reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of
Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

    	 

     

    

 

(b)
Mechanics of Exercise.

 

i.
Delivery of Certificates Upon Exercise. Certificates for Warrant Shares purchased hereunder shall be delivered to the address
specified by the Holder in the Notice of Exercise within the first 10 Business Days of the month following the month in which
the Notice of Exercise Form and payment of the aggregate Exercise Price is delivered to the Company (the “Delivery
Date”). This Warrant shall be deemed to have been exercised on the date the Exercise Price is received by the Company.
The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall
be deemed to have become a holder of record of such Warrant Shares for all purposes, as of the date the Warrant has been exercised
by payment to the Company of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to Section
1(b)(v) prior to the issuance of such securities, have been paid.

 

ii.
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing
Warrant Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called
for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

 

iii.
Rescission Rights. If the Company fails to deliver to the Holder a certificate or the certificates representing the Warrant
Shares pursuant to Section 1(b)(i) by the Delivery Date, then, the Holder will have the right to rescind such exercise.

 

iv.
No Fractional Shares or Scrip. No fractional Shares or scrip representing fractional Warrant Shares shall be issued upon
the exercise of this Warrant. As to any fraction of a Share which Holder would otherwise be entitled to purchase upon such exercise,
the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such
fraction multiplied by the Exercise Price or round up to the next whole Share.

 

v.
Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for
any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses
shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may
be directed by the Holder; provided, however, that in the event certificates for Warrant Shares are to be issued in a name
other than the name of the Holder, the Holder shall deliver to the Company the Assignment Form attached hereto duly executed by
the Holder, and follow the requirements set forth in Section 3(d). The Company may require, as a condition thereto, the
payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.

 

    	Nexien BioPharma, Inc. Class B Purchase Warrant – page 2

     

    

 

vi.
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

(c)
Cashless Exercise. This Warrant may also be exercised, in whole or in part, at such time by means of a “cashless
exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by
dividing [(A-B) (X)] by (A), where:

 

	 	(A)
    = 	the
    VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a “cashless
    exercise,” as set forth in the applicable Notice of Exercise;
	 	 	 
	 	(B)
    = 	the
    Exercise Price of this Warrant, as adjusted hereunder; and
	 	 	 
	 	(X)
    = 	the
    number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
    if such exercise were by means of a cash exercise rather than a cashless exercise.

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised, and the
holding period of the Warrants being exercised may be tacked on to the holding period of the Warrant Shares. The Company agrees
not to take any position contrary to this Section 1(c).

 

Section
2. Certain Adjustments.

 

a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event and the number of Warrant Shares issuable upon exercise of this Warrant shall be proportionately
adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section
2(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such
dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.

 

    	Nexien BioPharma, Inc. Class B Purchase Warrant – page 3

     

    

 

b)
Calculations. All calculations under this Section 2 shall be made to the nearest cent or the nearest 1/100th of
a share, as the case may be. For purposes of this Section 2, the number of shares of Common Stock deemed to be issued and
outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued
and outstanding.

 

c)
Notice to Holder.

 

i.
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 2,
the Company shall promptly mail/e-mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting
forth a brief statement of the facts requiring such adjustment.

 

ii.
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a
party, any sale or transfer of all or substantially all of the assets of the Company, of any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed/emailed
to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 5 Business Days prior
to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken
for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is
expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall
be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or
in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice.

 

The
Holder is entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the
event triggering such notice.

 

Section
3. Transfer of Warrant.

 

a)
Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section 3(c)
hereof, this Warrant and all rights hereunder are transferable, in whole only, upon surrender of this Warrant at the principal
office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached
hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making
of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant in the
name of the assignee, and this Warrant shall promptly be cancelled. The Warrant, if properly assigned, may be exercised by a new
holder for the purchase of Warrant Shares without having a new Warrant issued.

 

    	Nexien BioPharma, Inc. Class B Purchase Warrant – page 4

     

    

 

b)
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

c)
Transfer Restrictions. Any requested transfer of this Warrant, in whole only, shall be made by delivering to the Company
the Assignment Form and a Certificate of Accredited Investor Status completed by the proposed transferee(s). If the requested
transfer is approved by the Company in its sole discretion, a new Warrant shall be issued to the transferee(s).

 

Section
4. Miscellaneous.

 

a)
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 1(b)(i).

 

b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.

 

d)
Authorized Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized
and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of
any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full
authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates
for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable
law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant, be duly authorized, validly issued, fully paid and nonassessable and free
from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
occurring contemporaneously with such issue).

 

    	Nexien BioPharma, Inc. Class B Purchase Warrant – page 5

     

    

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.

 

e)
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be determined in accordance with the corporate laws of the State of Delaware.

 

f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
will have restrictions upon resale imposed by state and federal securities laws.

 

g)
Nonwaiver. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the fact that all
rights hereunder terminate on the Termination Date.

 

h)
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company
shall be delivered to the Holder at his/her/its last known address appearing in the Warrant Register of the Company.

 

i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability
of Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.

 

    	Nexien BioPharma, Inc. Class B Purchase Warrant – page 6

     

    

 

j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not
be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be
enforceable by the Holder or holder of Warrant Shares.

 

l)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and Holders holding at least a majority of the outstanding Class B Warrants.

 

m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.

 

********************

 

(Signature
Page Follow)

 

    	Nexien BioPharma, Inc. Class B Purchase Warrant – page 7

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Class B Warrant to be executed by its officer thereunto duly authorized as of the
date first above indicated.

 

	 	NEXIEN
    BIOPHARMA, INC.
	 	 	 
	 	By:
    	 /s/
    Evan Wasoff
	 	 	 Evan
    Wasoff, Chief Financial Officer

 

    	Nexien BioPharma, Inc. Class B Purchase Warrant – page 8

     

    

 

NOTICE
OF EXERCISE

 

	TO:
    	NEXIDEN
    BIOPHARMA INC.

 

	(1)	The
    undersigned hereby elects to purchase ________ shares of Common Stock of the Company (the “Warrant Shares”)
    pursuant to the terms of the attached Class B Warrant (only if exercised in full), and tenders herewith payment of the exercise
    price in full, together with all applicable transfer taxes, if any.
	 	 
	(2)	 Please
    issue a certificate or certificates representing said Warrant Shares [  ] in the name of the undersigned or [  ]
    in such other name as is specified below:

 

	 
	 

 

	(3)	The
    undersigned acknowledges that the Warrant Shares have not been registered under the Securities Act of 1933, as amended (the
    “1933 Act”). Accordingly, the undersigned acknowledges, represents, warrants and agrees as follows:
	 	 	 
	 	a)	The
    Warrant Shares are being acquired for the undersigned’s own account for investment purposes only and with no view to
    their resale or other distribution of any kind, and no other person (except the spouse of the undersigned, if married) will
    own any interest therein.
	 	 	 
	 	b)	The
    undersigned will not sell or dispose of the Warrant Shares in violation of the 1933 Act, or any other applicable federal or
    state securities laws.
	 	 	 
	 	c)	The
    undersigned agrees that the Company may, without liability for its good faith actions, place legend restrictions upon the
    Warrant Shares and issue “stop transfer” instructions requiring compliance with applicable securities laws and
    the terms of the Class B Warrant.
	 	 	 
	 	d)	The
    undersigned represents, warrants and agrees, as of the date of this Notice of Exercise, that the undersigned continues to
    be an “accredited investor” as defined in the rules and regulations promulgated under the 1933 Act.

 

	 	 	 
	Name
    of Holder (Printed)	 	Signature
	 

         
	 	 

         

	Name
                                         of Holder’s Spouse (if name appears on this Warrant)

         

         
	 	Title
                                         (if applicable)

         

         

	Date	 	Address

         

         

 

    	Nexien BioPharma, Inc. Class B Purchase Warrant – page 9

     

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing warrant, execute this form and supply required information.

Do
not use this form to exercise the warrant.)

 

FOR
VALUE RECEIVED, [____] all of or [_______] Warrants of the foregoing Warrant and all rights evidenced thereby are hereby assigned
to

 

__________________________________________________________________________________
whose address is

 

________________________________________________________________________________________________

 

________________________________________________________________________________________________

 

	 	 	 
	Name
    of Holder (Printed)	 	Signature
	 

         
	 	 

         

	Name
                                         of Holder’s Spouse (if name appears on this Warrant)

         

         
	 	Title
                                         (if applicable)

         

         

	Date	 	Address

         

         

 

    	Nexien BioPharma, Inc. Class B Purchase Warrant – page 10

     

    

 

CERTIFICATE
OF ACCREDITED INVESTOR STATUS

 

Except
as may be indicated by the undersigned below, the undersigned is an individual “accredited investor,” as that term
is defined in Regulation D under the Securities Act of 1933, as amended (the “Act”). The undersigned has checked
the box below indicating the basis on which it is representing its status as an “accredited investor”:

 

	[  ]	a
    bank as defined in Section 3(a)(2) of the Act, or any savings and loan association or other institution as defined in Section
    3(a)(5)(A) of the Act whether acting in its individual or fiduciary capacity; a broker or dealer registered pursuant to Section
    15 of the Securities Exchange Act of 1934; an insurance company as defined in Section 2(a)(13) of the Act; an investment company
    registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that
    act; a small business investment company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of
    the Small Business Investment Act of 1958; a plan established and maintained by a state, its political subdivisions, or any
    agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total
    assets in excess of $5,000,000; an employee benefit plan within the meaning of the Employee Retirement Income Security Act
    of 1974, if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such act, which is either
    a bank, savings and loan association, insurance company, or registered investment adviser, or if the employee benefit plan
    has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons that
    are “accredited investors”;
	 	 
	[  ]	a
    private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940;
	 	 
	[  ]	an
    organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts or similar business trust,
    or partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000;
	 	 
	[  ]	a
    natural person whose individual net worth, or joint net worth with the undersigned’s spouse, excluding the “net
    value” of his or her primary residence, at the time of this purchase exceeds $1,000,000 and having no reason to believe
    that net worth will not remain in excess of $1,000,000 for the foreseeable future, with “net value” for such purposes
    being the fair value of the residence less any mortgage indebtedness or other obligation secured by the residence, but subtracting
    such indebtedness or obligation only if it is a liability already considered in calculating net worth;
	 	 
	[  ]	a
    natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with
    the undersigned’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the
    same income level in the current year;
	 	 
	[  ]	a
    trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered,
    whose purchase is directed by a person who has such knowledge and experience in financial and business matters that he is
    capable of evaluating the merits and risks of the prospective investment; or
	 	 
	[  ]	an
    entity in which all of the equity holders are “accredited investors” by virtue of their meeting one or more of
    the above standards.
	 	 
	[  ]	an
    individual who is a director or executive officer of Intiva BioPharma Inc.

 

IN
WITNESS WHEREOF, the undersigned has executed this Certificate of Accredited Investor Status effective as of __________________,
20__.

 

	Date:
    	 	 	 
	 	 	 	Subscriber
    Name (Printed)
	 	 	 	 	              
	 	 	 	By:	 
	 	 	 	 	 
	 	 	 	Name:	 
	 	 	 	 	 
	 	 	 	Title:
    	 

 

    	Nexien BioPharma, Inc. Class B Purchase Warrant – page 11

     

    

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

CLASS
C PURCHASE WARRANT

 

NEXIEN
BIOPHARMA, INC.

 

Issue
Date: November 24, 2020

Warrant
No. C-001

 

THIS
CLASS C PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Richard Greenberg
(the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after the Issue Date (the “Initial Exercise Date”) and on or
prior to 5:00 p.m. Mountain Time on November 24, 2025 (the “Termination Date”) but not thereafter,
to subscribe for and purchase from NEXIEN BIOPHARMA, INC., a Delaware corporation (the “Company”), up
to 1,062,953 shares of Common Stock (the “Warrant Shares”) at a price equal to the lesser of
(i) $0.045157 per share and (ii) 120% of the Conversion Price of that certain Convertible Promissory Note made and delivered as
of the Issue Date of this Warrant to the Holder in effect as of the date of exercise (the “Exercise Price”).

 

Section
1. Exercise.

 

a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date, by delivery to the Company (or such
other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the
Holder appearing on the books of the Company) of a facsimile or scanned copy of the duly executed Notice of Exercise Form annexed
hereto; and, within 3 Business Days of the date said Notice of Exercise is delivered to the Company, the Company shall have received
payment of the aggregate Exercise Price of the Warrant Shares thereby purchased by wire transfer or cashier’s check drawn
on a United States bank. The Holder shall not be required to physically surrender this Warrant to the Company upon exercise. Partial
exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall
have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable
number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased
and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within 2 Business Days
of receipt of such notice. In the event of any dispute or discrepancy, the records of the Company shall be controlling and determinative
in the absence of manifest error. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by
reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of
Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

    	 

    	 

    

 

(b)
Mechanics of Exercise.

 

i.
Delivery of Certificates Upon Exercise. Certificates for Warrant Shares purchased hereunder shall be delivered to the address
specified by the Holder in the Notice of Exercise within the first 10 Business Days of the month following the month in which
the Notice of Exercise Form and payment of the aggregate Exercise Price is delivered to the Company (the “Delivery
Date”). This Warrant shall be deemed to have been exercised on the date the Exercise Price is received by the Company.
The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall
be deemed to have become a holder of record of such Warrant Shares for all purposes, as of the date the Warrant has been exercised
by payment to the Company of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to Section
1(b)(v) prior to the issuance of such securities, have been paid.

 

ii.
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing
Warrant Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called
for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

 

iii.
Rescission Rights. If the Company fails to deliver to the Holder a certificate or the certificates representing the Warrant
Shares pursuant to Section 1(b)(i) by the Delivery Date, then, the Holder will have the right to rescind such exercise.

 

iv.
No Fractional Shares or Scrip. No fractional Shares or scrip representing fractional Warrant Shares shall be issued upon
the exercise of this Warrant. As to any fraction of a Share which Holder would otherwise be entitled to purchase upon such exercise,
the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such
fraction multiplied by the Exercise Price or round up to the next whole Share.

 

v.
Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for
any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses
shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may
be directed by the Holder; provided, however, that in the event certificates for Warrant Shares are to be issued in a name
other than the name of the Holder, the Holder shall deliver to the Company the Assignment Form attached hereto duly executed by
the Holder, and follow the requirements set forth in Section 3(d). The Company may require, as a condition thereto, the
payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.

 

    	Nexien BioPharma, Inc. Class C Purchase Warrant – page 2

     

    

 

vi.
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

(c)
Cashless Exercise. This Warrant may also be exercised, in whole or in part, at such time by means of a “cashless
exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by
dividing [(A-B) (X)] by (A), where:

 

(A)
= the VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a “cashless
exercise,” as set forth in the applicable Notice of Exercise;

 

(B)
= the Exercise Price of this Warrant, as adjusted hereunder; and

 

(X)
= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
if such exercise were by means of a cash exercise rather than a cashless exercise.

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised, and the
holding period of the Warrants being exercised may be tacked on to the holding period of the Warrant Shares. The Company agrees
not to take any position contrary to this Section 1(c).

 

Section
2. Certain Adjustments.

 

a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event and the number of Warrant Shares issuable upon exercise of this Warrant shall be proportionately
adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section
2(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such
dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.

 

    	Nexien BioPharma, Inc. Class C Purchase Warrant – page 3

     

    

 

b)
Calculations. All calculations under this Section 2 shall be made to the nearest cent or the nearest 1/100th of
a share, as the case may be. For purposes of this Section 2, the number of shares of Common Stock deemed to be issued and
outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued
and outstanding.

 

c)
Notice to Holder.

 

i.
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 2,
the Company shall promptly mail/e-mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting
forth a brief statement of the facts requiring such adjustment.

 

ii.
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a
party, any sale or transfer of all or substantially all of the assets of the Company, of any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed/emailed
to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 5 Business Days prior
to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken
for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is
expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall
be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or
in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice.

 

The
Holder is entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the
event triggering such notice.

 

Section
3. Transfer of Warrant.

 

a)
Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section 3(c)
hereof, this Warrant and all rights hereunder are transferable, in whole only, upon surrender of this Warrant at the principal
office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached
hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making
of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant in the
name of the assignee, and this Warrant shall promptly be cancelled. The Warrant, if properly assigned, may be exercised by a new
holder for the purchase of Warrant Shares without having a new Warrant issued.

 

    	Nexien BioPharma, Inc. Class C Purchase Warrant – page 4

     

    

 

b)
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

c)
Transfer Restrictions. Any requested transfer of this Warrant, in whole only, shall be made by delivering to the Company
the Assignment Form and a Certificate of Accredited Investor Status completed by the proposed transferee(s). If the requested
transfer is approved by the Company in its sole discretion, a new Warrant shall be issued to the transferee(s).

 

Section
4. Miscellaneous.

 

a)
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 1(b)(i).

 

b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.

 

d)
Authorized Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized
and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of
any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full
authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates
for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable
law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant, be duly authorized, validly issued, fully paid and nonassessable and free
from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
occurring contemporaneously with such issue).

 

    	Nexien BioPharma, Inc. Class C Purchase Warrant – page 5

     

    

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.

 

e)
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be determined in accordance with the corporate laws of the State of Delaware.

 

f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
will have restrictions upon resale imposed by state and federal securities laws.

 

g)
Nonwaiver. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the fact that all
rights hereunder terminate on the Termination Date.

 

h)
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company
shall be delivered to the Holder at his/her/its last known address appearing in the Warrant Register of the Company.

 

i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability
of Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.

 

    	Nexien BioPharma, Inc. Class C Purchase Warrant – page 6

     

    

 

j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not
be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be
enforceable by the Holder or holder of Warrant Shares.

 

l)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and Holders holding at least a majority of the outstanding Class C Warrants.

 

m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.

 

********************

 

(Signature
Page Follow)

 

    	Nexien BioPharma, Inc. Class C Purchase Warrant – page 7

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Class C Warrant to be executed by its officer thereunto duly authorized as of the
date first above indicated.

 

	 	 	NEXIEN
    BIOPHARMA, INC.
	 	 	 	 
	 	 	By:
    	/s/
    Evan Wasoff
	 	 	 	Evan
    Wasoff, Chief Financial Officer

 

    	Nexien BioPharma, Inc. Class C Purchase Warrant – page 8

     

    

 

NOTICE
OF EXERCISE

 

	TO:
    	NEXIDEN
    BIOPHARMA INC.

 

	(1)	The undersigned
    hereby elects to purchase ________ shares of Common Stock of the Company (the “Warrant Shares”)
    pursuant to the terms of the attached Class C Warrant (only if exercised in full), and tenders herewith payment of the exercise
    price in full, together with all applicable transfer taxes, if any.
	 	 
	(2)	Please issue a certificate
    or certificates representing said Warrant Shares [  ] in the name of the undersigned or [  ] in such other
    name as is specified below:
	 	 
	 	 
	 	 
	 	 
	(3)	The undersigned acknowledges that the Warrant
    Shares have not been registered under the Securities Act of 1933, as amended (the “1933 Act”). Accordingly,
    the undersigned acknowledges, represents, warrants and agrees as follows:

 

	 	a)	The
    Warrant Shares are being acquired for the undersigned’s own account for investment purposes only and with no view to
    their resale or other distribution of any kind, and no other person (except the spouse of the undersigned, if married) will
    own any interest therein.
	 	 	 
	 	b)	The
    undersigned will not sell or dispose of the Warrant Shares in violation of the 1933 Act, or any other applicable federal or
    state securities laws.
	 	 	 
	 	c)	The
    undersigned agrees that the Company may, without liability for its good faith actions, place legend restrictions upon the
    Warrant Shares and issue “stop transfer” instructions requiring compliance with applicable securities laws and
    the terms of the Class C Warrant.
	 	 	 
	 	d)	The
    undersigned represents, warrants and agrees, as of the date of this Notice of Exercise, that the undersigned continues to
    be an “accredited investor” as defined in the rules and regulations promulgated under the 1933 Act.

 

	 	 	 
	Name
    of Holder (Printed)	 	Signature
	 	 	 
	 	 	 
	Name
                                         of Holder’s Spouse (if name appears on this Warrant)

         

         
	 	Title
                                         (if applicable)

         

         

	Date	 	Address
	 	 	 

 

    	Nexien BioPharma, Inc. Class C Purchase Warrant – page 9

     

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing warrant, execute this form and supply required information.

Do
not use this form to exercise the warrant.)

 

FOR
VALUE RECEIVED, [____] all of or [_______] Warrants of the foregoing Warrant and all rights evidenced thereby are hereby assigned
to

 

__________________________________________________________________________________whose
address is

 

_______________________________________________________________________________________________

 

_______________________________________________________________________________________________ 

 

  

	 	 	 
	Name
    of Holder (Printed)	 	Signature
	 

         
	 	 

         

	Name
                                         of Holder’s Spouse (if name appears on this Warrant)

         

         
	 	Title
                                         (if applicable)

         

         

	Date	 	Address

         

         

 

    	Nexien BioPharma, Inc. Class C Purchase Warrant – page 10

     

    

 

CERTIFICATE
OF ACCREDITED INVESTOR STATUS

 

Except
as may be indicated by the undersigned below, the undersigned is an individual “accredited investor,” as that term
is defined in Regulation D under the Securities Act of 1933, as amended (the “Act”). The undersigned has checked
the box below indicating the basis on which it is representing its status as an “accredited investor”:

 

	[  ]	a
    bank as defined in Section 3(a)(2) of the Act, or any savings and loan association or other institution as defined in Section
    3(a)(5)(A) of the Act whether acting in its individual or fiduciary capacity; a broker or dealer registered pursuant to Section
    15 of the Securities Exchange Act of 1934; an insurance company as defined in Section 2(a)(13) of the Act; an investment company
    registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that
    act; a small business investment company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of
    the Small Business Investment Act of 1958; a plan established and maintained by a state, its political subdivisions, or any
    agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total
    assets in excess of $5,000,000; an employee benefit plan within the meaning of the Employee Retirement Income Security Act
    of 1974, if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such act, which is either
    a bank, savings and loan association, insurance company, or registered investment adviser, or if the employee benefit plan
    has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons that
    are “accredited investors”;
	 	 
	[  ]	a
    private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940;
	 	 
	[  ]	an
    organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts or similar business trust,
    or partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000;
	 	 
	[  ]	a
    natural person whose individual net worth, or joint net worth with the undersigned’s spouse, excluding the “net
    value” of his or her primary residence, at the time of this purchase exceeds $1,000,000 and having no reason to believe
    that net worth will not remain in excess of $1,000,000 for the foreseeable future, with “net value” for such purposes
    being the fair value of the residence less any mortgage indebtedness or other obligation secured by the residence, but subtracting
    such indebtedness or obligation only if it is a liability already considered in calculating net worth;
	 	 
	[  ]	a
    natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with
    the undersigned’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the
    same income level in the current year;
	 	 
	[  ]	a
    trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered,
    whose purchase is directed by a person who has such knowledge and experience in financial and business matters that he is
    capable of evaluating the merits and risks of the prospective investment; or
	 	 
	[  ]	an
    entity in which all of the equity holders are “accredited investors” by virtue of their meeting one or more of
    the above standards.
	 	 
	[  ]	an
    individual who is a director or executive officer of Intiva BioPharma Inc.

 

IN
WITNESS WHEREOF, the undersigned has executed this Certificate of Accredited Investor Status effective as of __________________,
20__.

 

	Date:
    	 	 	 
	 	 	 	Subscriber
    Name (Printed)
	 	 	 	 	 
	 	 	 	By:	 
	 	 	 	 	 
	 	 	 	Name:	 
	 	 	 	 	 
	 	 	 	Title:	 

 

    	Nexien BioPharma, Inc. Class C Purchase Warrant – page 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}]]